Clinical trials: Vaccine Response
Malignant Pleural Mesothelioma
Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma
This clinical trial will evaluate the safety and immune response of the sequential administration cancer vaccine CRS-207 (with or without cyclophosphamide) followed by standard of care chemotherapy (pemetrexed and cisplatin).
- Trial name
- NCT01675765
- Testing
- Immunotherapy plus chemotherapy, Immunotherapy with cyclophosphamide plus chemotherapy
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- Aduro Biotech, Inc.
Obstructive Sleep Apnea
Immunological Consequences of Obstructive Sleep Apnea
Obstructive sleep apnea (OSA) is a medical problem whose importance is increasing in recognition and awareness. OSA is associated with the development of hypertension and other cardiovascular diseases (1,2).
- Trial name
- NCT00214071
- Testing
- Influenza vaccine
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Respiratory Syncytial Virus Infections
An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study
The purpose of this study is: To investigate the optimal timing for revaccination after the initial RSVPreF3 OA vaccine dose, To evaluate the long-term immune persistence and safety up to 5 consecutive RSV seasons (approximately…
- Trial name
- RSV OA=ADJ=012 (NCT06534892)
- Testing
- RSVPreF3 OA vaccine
- Where
- 251 sites in United States, Australia and 15 more
- Volunteers
- 10,212 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Meningococcal Disease
Phase 2, Observer-Blind, Placebo-Controlled, Randomized, Multi-Center Extension Study to Evaluate the Safety and Immunogenicity of a Booster Dose of a MenABCWY Vaccine Administered 24 Months Following the Primary Series to Adolescents and Young Adults Who Participated in V102_03 (NCT01272180)
The purpose of this extension study is to evaluate the immunogenicity and safety of a booster dose of a MenABCWY vaccine, administered 24 months after completion of the primary vaccination series, in subjects who previously…
- Trial name
- NCT01992536
- Testing
- MenABCWY+OMV, MenABCWY+¼OMV
- Where
- 13 sites in United States, Poland
- Volunteers
- 194 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Pancreatic Cancer
Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer
The purpose of this study is to study the safety and clinical activity of nivolumab and ipilimumab in combination with either sequential administration of CY/GVAX pancreas vaccine followed by CRS-207 (Arm A) or with…
- Trial name
- NCT03190265
- Testing
- Cyclophosphamide, Nivolumab, Ipilimumab
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Meningococcal Serogroup B
Pilot Study of the Immunogenicity, Reactogenicity and Tolerability of Two Schedules of a 4CmenB Vaccine in Adolescents and Young Adults
The overall aim of this study is to determine if an accelerated "Bexsero® (Multicomponent meningococcal B vaccine)" schedule compared to a standard schedule is immunogenic, safe, and tolerable, in order to increase capacity for…
- Trial name
- NCT02583412
- Testing
- Bexsero®, Havrix®
- Where
- Canada
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Canadian Immunization Research Network
HIV Infections
Evaluating the Safety of and Immune Response to an HIV Vaccine in Healthy, HIV-Uninfected Adults in Uganda
The RV 156A clinical trial is evaluating an experimental HIV vaccine in people who are not infected with HIV. Participants in that study are randomly assigned to receive either the HIV vaccine or placebo.
- Trial name
- NCT01549509
- Testing
- VRC-HIVADV014-00-VP Vaccine
- Where
- Uganda
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Obesity
Effect of Obesity on Immune Response to Pneumovax 23
Pneumococcal infections are a leading cause of adult and childhood hospitalization and death. It has been shown that obese individuals are at higher risk for this bacterial infection.
- Trial name
- ROVE (NCT02471014)
- Testing
- Pneumovax 23, Blood tests, Questionnaires
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Florida
Malaria
Markers of T Cell Suppression: Antimalarial Treatment and Vaccine Responses in Healthy Malian Adults
Background: People with malaria often show altered immune responses to many illnesses and vaccines. This means that the malaria might cause immune suppression. It is not clear how or which vaccines are impacted by malaria.
- Trial name
- NCT02544048
- Where
- Mali
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
Effect of Age and Prior Immunity to Response to Seasonal Influenza Vaccines in Children
A total of 88 children between 2 and 9 years of age will be randomized to receive a two dose schedule of either licensed live attenuated trivalent seasonal influenza vaccine (LAIV) or licensed inactivated seasonal influenza…
- Trial name
- NCT01246999
- Testing
- Live attenuated Influenza vaccine, Trivalent Influenza Vaccine, TIV followed by LAIV
- Where
- 2 sites in United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- University of Rochester
Staphylococcus Aureus, Bacteremia
Efficacy, Immunogenicity, and Safety of a Single Dose of V710 in Adult Patients Scheduled for Cardiothoracic Surgery (V710-003 AM2)
This study will assess the efficacy of a single dose of V710 vaccine to prevent serious Staphylococcus aureus infections following elective cardiothoracic surgery.
- Conditions
- Staphylococcus Aureus, Bacteremia, Mediastinitis
- Trial name
- NCT00518687
- Testing
- V710
- Volunteers
- 8,031 people
- Sponsor
- Merck Sharp & Dohme LLC
Multiple Myeloma
Study of Tecemotide (L-BLP25) in Subjects With Slowly Progressive Multiple Myeloma With no Symptoms and Who Have Had no Chemotherapy
Tecemotide (L-BLP25) is believed to induce a Mucinous glycoprotein 1 (MUC1)-specific T-cell response after vaccination. The primary purpose of this study is to ascertain whether vaccination with tecemotide (L-BLP25) induces a…
- Trial name
- NCT01094548
- Testing
- Tecemotide (L-BLP25), Single low dose cyclophosphamide, Multiple low dose cyclophosphamide
- Where
- Germany
- Volunteers
- 34 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
HPV-Related Carcinoma
Effectiveness and B-memory Cell Response to QHPV Vaccine 9-years Post-vaccination Among HIV-infected Boys and Girls
In 2013, the Investigators enrolled a cohort of 180 HIV-1 infected adolescent girls and boys ages 9-14 years and administered three doses of the QHPV vaccine (NCT04711265).
- Trial name
- NCT04920526
- Testing
- Quadrivalent HPV [Type 6, 11, 16 and 18] L1 Virus-Like Particle Vaccine
- Volunteers
- 135 people
- Sponsor
- Kenya Medical Research Institute
COVID-19 Vaccines, Varicella Zoster Vaccine
PREPARE-iVAC Trial
Objective: To investigate whether replacement of MMF/MPA by everolimus in kidney transplant recipients results in superior immunogenicity of COVID-19 vaccination as measured by neutralizing antibody titer against the Omicron…
- Conditions
- COVID-19 Vaccines, Varicella Zoster Vaccine, Vaccine Response, Immunosuppression
- Trial name
- PREPARE-iVAC (NCT05924685)
- Testing
- COVID-19 vaccination
- Where
- 7 sites in Netherlands
- Volunteers
- 110 people
- Sponsor
- University Medical Center Groningen
Hepatitis B
Comparison of Monodose and Multidose Presentations of GSK Biologicals' Hepatitis B Vaccine in Terms of Immune Response
GSK Biologicals' currently licensed multidose hepatitis B vaccine will be compared to the currently licensed monodose hepatitis B vaccine in a population with well documented hepatitis B immunological response to the vaccine…
- Trial name
- NCT00197158
- Testing
- Hepatitis B vaccine
- Where
- Belgium
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COPD, RSV
RSV Vaccination to Reduce Recurrent AECOPD
Objectives: To determine whether respiratory syncytial virus (RSV) vaccination reduces the rate of all-cause moderate-to-severe acute exacerbations of COPD (AECOPD) in high-risk patients, and to characterise RSV-specific…
- Trial name
- NCT07508644
- Testing
- RSV vaccination (Arexvy, GlaxoSmithKline)
- Where
- Hong Kong
- Volunteers
- 320 people
- Sponsor
- Chinese University of Hong Kong
Dengue Shock Syndrome, Dengue Hemorrhagic Fever
Safety of and Immune Response to DEN4 Vaccine Component Candidate for Dengue Virus
Infection with dengue viruses is one of the leading causes of hospitalization and death in children in several tropical Asian counties.
- Trial name
- NCT00919178
- Testing
- DEN4 Vaccine Candidate
- Where
- 2 sites in United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Asthma
Immune Response to Pneumococcal Polysaccharide Vaccine (23-valent) Predicts Asthma Status and Outcomes in Late Adolescents With Asthma
Advisory Committee for Immunization Practices (ACIP) from the Centers for Disease Control (CDC) recommends that children (6-18 years) and adults (≥19 years old) with chronic lung condition such as asthma or cigarette smoking be…
- Trial name
- NCT02719379
- Testing
- Pneumonococcal Polysaccharide Vaccine 23-valent (PPSV-23)
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Rohit Divekar
Meningitis, Meningococcal Disease
Understanding the Immune Response to Two Different Meningitis Vaccines
The bacterium (germ) Neisseria meningitidis causes meningitis and blood poisoning. N meningitidis is classified into different serogroups (types), based on its outer polysaccharide (carbohydrate) capsule.
- Conditions
- Meningitis, Meningococcal Disease, Septicaemia
- Trial name
- NCT01593514
- Testing
- MenACWY-CRM conjugate vaccine (Menveo, Novartis), MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) and MenACWY-CRM conjugate vaccine (Menveo, Novartis), 1/5th dose MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) and MenACWY-CRM conjugate vaccine (Menveo, Novartis)
- Where
- United Kingdom
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Oxford
RSV Infection
RSV Vaccination in Immunocompromised Patients.
Respiratory syncytial Virus (RSV) causes respiratory infections worldwide and typically presents with a seasonal pattern peaking in autumn/winter in temperate climate zones.
- Trial name
- NCT06597916
- Testing
- Arexvy powder and suspension for injection
- Where
- Austria
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.